Bionanosensors in early-stage theragnostics

The thesis focuses on the development and application of nanomaterials in the field of theranostics, combining diagnostics and targeted drug delivery within the framework of personalized medicine. The primary objective is to design and test ultrasensitive and mechanically stable bionanosensors based on nanofiber membranes that are able to detect the early stages of diseases. These sensors, functionally modified with specific molecular binding agents, will enable the accurate detection of biomarkers such as proteins, antibodies, bacteria, and microRNAs, significantly enhancing and expanding diagnostic capabilities. The secondary goal is to develop and test systems for active targeted drug delivery, including implantable gels, protective/prophylactic devices, and on-tissue systems such as regenerative skin coverings. The theoretical section summarizes current knowledge on biomarkers, nanotechnology, and targeted drug delivery methods, particularly in oncology and degenerative diseases. The experimental section demonstrates the detection of bacterial contamination using nanofiber-based sensors that are able to identify Escherichia coli and other biomolecules in various model fluids. The results confirm the potential of these technologies not only for the early diagnosis of infections and cancer but also for the advancement of active targeted drug delivery delivery systems in regenerative medicine. The research also addresses the limitations of traditional methods, such as the low specificity and limited accessibility of imaging techniques and the side effects of passive drug delivery. It offers a promising direction for modern diagnostic and therapeutic strategies.

The thesis focuses on the development and application of nanomaterials in the field of theranostics, combining diagnostics and targeted drug delivery within the framework of personalized medicine. The primary objective is to design and test ultrasensitive and mechanically stable bionanosensors based on nanofiber membranes that are able to detect the early stages of diseases. These sensors, functionally modified with specific molecular binding agents, will enable the accurate detection of biomarkers such as proteins, antibodies, bacteria, and microRNAs, significantly enhancing and expanding diagnostic capabilities. The secondary goal is to develop and test systems for active targeted drug delivery, including implantable gels, protective/prophylactic devices, and on-tissue systems such as regenerative skin coverings. The theoretical section summarizes current knowledge on biomarkers, nanotechnology, and targeted drug delivery methods, particularly in oncology and degenerative diseases. The experimental section demonstrates the detection of bacterial contamination using nanofiber-based sensors that are able to identify Escherichia coli and other biomolecules in various model fluids. The results confirm the potential of these technologies not only for the early diagnosis of infections and cancer but also for the advancement of active targeted drug delivery systems in regenerative medicine. The research also addresses the limitations of traditional methods, such as the low specificity and limited accessibility of imaging techniques and the side effects of passive drug delivery. It offers a promising direction for modern diagnostic and therapeutic strategies